Compare iShares MSCI Canada (TSX) (EWC) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Canada (TSX) vs Johnson & Johnson — how do they compare? iShares MSCI Canada (TSX) trades at $59.41, while Johnson & Johnson trades at $250.18 (market cap $594.63B). The key difference: Johnson & Johnson pays a 2.17% dividend while iShares MSCI Canada (TSX) pays none, and iShares MSCI Canada (TSX) is trading nearer its 52-week high, Johnson & Johnson nearer its low. Which is the better fit depends on your goals.
| EWC | JNJ | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $59.49 | $267.24 |
52-Week Low | $45.86 | $162.98 |
Market Cap | — | $594.63B |
Volume | — | 6,156,228 |
Enterprise Value | — | $627.57B |
Dividend Yield | — | 2.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWC trades at $59.38, up 0.34% today, with a bullish technical signal from moving averages but overbought RSI readings. The stock shows strong momentum near key resistance at $60, supported by positive Canadian economic news including trade surpluses and nuclear energy expansion plans. A dividend of $0.28 is scheduled for June 2026, adding income appeal.
Outlook remains positive due to Canada's economic recovery and commodity strength, though risks include US trade policy uncertainty and high RSI levels suggesting near-term consolidation. Institutional sentiment is bullish, with technical support at $59 providing a floor for potential gains.
Johnson & Johnson (JNJ) trades at $253.85, down 1.52% on the day, with a bullish technical signal supported by moving averages. The company reported Q1 2026 earnings of $2.70 per share, beating estimates, and raised its full-year 2026 outlook. Revenue grew 6.6% annually in Q2 2026, driven by strength in Innovative Medicine and new product launches, though MedTech sales slightly missed expectations.
JNJ offers a compelling investment case with a 64-year dividend king status, robust profitability, and raised guidance, but faces risks from patent expirations and competitive pressures. Analyst consensus is bullish with a $281 price target, suggesting ~11% upside, supported by strong institutional confidence and innovation in AI and robotics targeting $100 billion revenue.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI Canada (TSX)
EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.
Read more on EWC →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
